Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


«12...1415161718192021222324...3839»
  • ||||||||||  [VIRTUAL] Injection-Site Reactions in the Randomized Phase 3 PEGASUS Trial of Pegcetacoplan Compared with Eculizumab for Individuals with Paroxysmal Nocturnal Hemoglobinuria () -  May 12, 2021 - Abstract #BSH2021BSH_455;    
    P3
    Five drugs with comparable delivery to pegcetacoplan were identified and evaluated for ISR data: immunoglobulin with hyaluronidase, deferoxamine, daratumumab and hyaluronidase, certolizumab pegol, and pegfilgrastim (see Table)...ISRs were often mild or manageable and pegcetacoplan patients on average reported higher quality of life than ECU treated patients, indicating these events are likely not a barrier to treatment. Comparable trends for reported ISRs have been observed with drugs delivered similarly to pegcetacoplan; management strategies for ISRs with these drugs may potentially be useful for reactions observed with pegcetacoplan.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Clinical, Journal, Real-world evidence:  Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis. (Pubmed Central) -  May 11, 2021   
    There were no significant differences among the CZP groups with and without MTX or the groups receiving the high vs. low MTX doses in the retention rate, the low disease activity rate, or the inhibitory effect in radiographic joint damage. CZP has the potential to be a useful biological agent to control RA's disease activity and the bone destruction in patients who cannot tolerate a sufficient MTX dose.
  • ||||||||||  Clinical, Journal, Real-world evidence:  Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data. (Pubmed Central) -  May 8, 2021   
    The percentages of effectively treated patients were generally lower in second-line treatment compared with first-line except for etanercept, which had the same percentage between lines of therapy. Etanercept had the lowest RA-related cost per effectively treated patient among tumor necrosis factor inhibitors in first-line use and the lowest RA-related cost per effectively treated patient compared with all second-line treatments.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents. (Pubmed Central) -  May 1, 2021   
    The intracellular pathways induced by MTX and anti-TNF agents seem to be independent. These findings might explain at least in part improved the clinical response upon co-therapy of MTX and an anti-TNF agent in RA.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) -  Apr 27, 2021   
    P1,  N=30, Active, not recruiting, 
    N=650 --> 390 Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
  • ||||||||||  Journal:  Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. (Pubmed Central) -  Apr 23, 2021   
    Anti-TNF agents (except certolizumab), vedolizumab, ustekinumab and tofacitinib readily traverse the placenta via active transport, therefore theoretically may affect fetal development...There is reasonable evidence to support the safety of anti-TNF agents during pregnancy and lactation, however some data suggests that combination therapy with thiopurines may increase the risk of pregnancy and neonatal complications, as well as childhood infections within the first year of life. Vedolizumab and ustekinumab are both thought to be safe in pregnancy and lactation, while tofacitinib is generally avoided due to teratogenic effects in animal studies.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Enrollment change:  UCB Cimzia Pregnancy Follow-up Study (clinicaltrials.gov) -  Apr 22, 2021   
    P=N/A,  N=1, Terminated, 
    Initiation date: Jan 2021 --> Jun 2021 N=360 --> 1
  • ||||||||||  Clinical, Review, Journal:  Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders. (Pubmed Central) -  Apr 13, 2021   
    However, as new therapeutics continue to be developed for the management of CTDs, the potential utility for anti-TNFα agents has become of great interest, demonstrated in several recent case series and small open-label trials. We review the safety and compatibility of anti-TNFα therapy in the management of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), two well-studied example CTDs, as well as summarize the risks of autoantibody generation, infection, malignancy, and iatrogenic lupus flares as side effects of blocking TNFα in patients with these conditions.
  • ||||||||||  [VIRTUAL] A Review of the Cost-Effectiveness of Secukinumab in the Management of Psoriatic Arthritis () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_82;    
    Based on the 7 international studies, secukinumab was more cost-effective than all other subcutaneous, intravenous, and oral biologics except ixekizumab. Factors that were found to influence cost-effectiveness of secukinumab included costs associated with drug acquisition, administration, adverse events, and monitoring; and patient factors such as PsA severity.
  • ||||||||||  [VIRTUAL] Comparative Efficacy of Treatments for Moderate-to-Severe Plaque Psoriasis: An Updated Network Meta-Analysis (NMA) () -  Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_251;    
    In the short term (N=69 RCTs), the PASI 90 rates were highest for ixekizumab (72.9%), risankizumab (72.9%), and brodalumab (72.3%), which were significantly higher than guselkumab (65.4%), secukinumab (65.4%), infliximab (56.4%), certolizumab (400 mg: 49.8%, 200 mg: 42.4%), ustekinumab (46.2%), adalimumab (44.2%), tildrakizumab (200 mg: 40.0%, 100 mg: 37.4%), etanercept (18.0%), dimethyl fumarate (12.8%), and apremilast (12.6%). Ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, and risankizumab had the highest long-term efficacy.
  • ||||||||||  [VIRTUAL] DOSING OF BDMARDS IN AXSPA AND PSA IN A REAL WORLD SETTING (Room 5) -  Apr 6, 2021 - Abstract #EULAR2021EULAR_1847;    
    While TNFi are used in licensed doses in most patients, non-TNFi-bDMARDs were often used in higher doses, which corresponds to higher doses approved in other indications like psoriasis. The effectiveness of this treatment strategy in axSpA and PsA needs to be analysed further.